William Richard White - Dec 27, 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Financial Officer
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Dec 27, 2022
Transactions value $
-$855,143
Form type
4
Date filed
12/29/2022, 04:41 PM
Previous filing
Dec 20, 2022
Next filing
Jan 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $133K +19K +80.43% $7.01* 42.6K Dec 27, 2022 Direct F1
transaction AKRO Common Stock Sale -$946K -19K -44.58% $49.77 23.6K Dec 27, 2022 Direct F1, F2
transaction AKRO Common Stock Options Exercise $7K +999 +4.23% $7.01* 24.6K Dec 28, 2022 Direct F1
transaction AKRO Common Stock Sale -$49.7K -999 -4.06% $49.76 23.6K Dec 28, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -19K -7.26% $0.00 243K Dec 27, 2022 Common Stock 19K $7.01 Direct F1, F4
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -999 -0.41% $0.00 242K Dec 28, 2022 Common Stock 999 $7.01 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2021, previously adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.75 to $49.84, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.75 to $49.785, inclusive.
F4 25% of this option vested on April 1, 2020, and the remaining 75% of this option shall vest in 36 equal monthly installments thereafter.